Does TALAZOPARIB Cause Tumour marker increased? 6 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Tumour marker increased have been filed in association with TALAZOPARIB (Talzenna). This represents 0.4% of all adverse event reports for TALAZOPARIB.
6
Reports of Tumour marker increased with TALAZOPARIB
0.4%
of all TALAZOPARIB reports
0
Deaths
0
Hospitalizations
How Dangerous Is Tumour marker increased From TALAZOPARIB?
Of the 6 reports.
Is Tumour marker increased Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TALAZOPARIB. However, 6 reports have been filed with the FAERS database.
What Other Side Effects Does TALAZOPARIB Cause?
Anaemia (219)
Neoplasm progression (169)
Death (142)
Off label use (78)
Thrombocytopenia (78)
Fatigue (77)
Platelet count decreased (68)
Haemoglobin decreased (65)
Febrile neutropenia (60)
Pancytopenia (60)
What Other Drugs Cause Tumour marker increased?
PALBOCICLIB (817)
FULVESTRANT (408)
NIRAPARIB (356)
LETROZOLE (343)
RIBOCICLIB (317)
RUCAPARIB CAMSYLATE (257)
CAPECITABINE (228)
EVEROLIMUS (228)
ELACESTRANT (222)
OLAPARIB (171)
Which TALAZOPARIB Alternatives Have Lower Tumour marker increased Risk?
TALAZOPARIB vs TALC
TALAZOPARIB vs TALIGLUCERASE ALFA
TALAZOPARIB vs TALIMOGENE LAHERPAREPVEC
TALAZOPARIB vs TALQUETAMAB
TALAZOPARIB vs TALQUETAMAB-TGVS